| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6100871 | Journal of Crohn's and Colitis | 2007 | 9 Pages |
Abstract
In anaemic IBD patients treated with IFX, combined administration of FeS is safe. Infliximab significantly increases serum EPO and sTFR levels resulting in an increased functional iron deficiency, which is restored after combined treatment with I.V. iron sucrose.
Keywords
i.v.TSATIBDQCDAIIFXIBDEPOFeSerythropoietinTransferrin saturationSafetyInfliximabCrohn's diseaseInflammatory bowel diseaseIntravenousIron sucroseCrohn's Disease Activity IndexVascular Endothelial Growth Factor (VEGF)haemoglobinInflammatory Bowel Disease QuestionnaireC-reactive proteinCRPanaemiaUlcerative colitis
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Konstantinos Katsanos, Etienne Cavalier, Marc Ferrante, Valérie Van Hauwaert, Liesbet Henckaerts, Fabian Schnitzler, Afroditi Katsaraki, Maja Noman, Séverine Vermeire, Epameinondas V. Tsianos, Paul Rutgeerts, Jean-Paul Chapelle, Gert Van Assche,